05.21.26 -- The U.S. Clinical Trial Recruiting Pipeline Report – May 2026

In the post-approval stage, a synergistic operating model brings PV and regulatory functions under one umbrella: a single governance structure with shared decision cycles, templates, and evidence.

Many clinical research routines are driven by habit, not regulation. This guide clears up 10 common misconceptions to streamline workflows and reduce unnecessary admin work.

Strengthen your research processes by adopting secure systems, staying current with regulatory standards, and ensuring your team is consistently trained to manage data responsibly and efficiently.

Real-world evidence is becoming vital in precision oncology. Discover five creative, practical ways sponsors can use RWE to fuel development, sharpen regulatory strategy, and strengthen market access.

Aligning clinical, regulatory, and operational strategies boosts biotech investment appeal. Strategic planning, clear milestones, and risk mitigation accelerate development and attract funding.

Stay ahead of the evolving UK regulatory landscape and leverage upcoming reforms to accelerate patient access, drive innovation, and strengthen your position in the medicines development market.

Senior experts from the HRA, the ISRCTN Registry (BMC), and Quotient Sciences discuss the implications of New UK regulations for sponsors' clinical trial registration and maintaining compliance.

The FDA’s 2026 guidance has put an end to "wellness by disclaimer." Learn how new standards for wearables and apps impact study design, participant safety, and the evolving ethical role of the IRB.

Emerging psychiatric therapies bring hope, but progress is fragile. Biomarker-driven, mechanism-first approaches help overcome biological, regulatory, and commercial barriers.

Discover how you can transform data management into a relationship-driven capability with the right partnership, achieving confidence, agility, and insight across the clinical trial lifecycle.

Accelerated development and manufacturing timelines provide developers with paths to move new therapies to market quickly while still maintaining a balance of risk/benefit assessment. 

Learn how to identify common CRO selection pitfalls and apply expert-backed strategies to protect your clinical program from costly risks and delays.